Systematic review and meta analysis

Work participation in patients with systemic lupus erythematosus: a systematic review

Birgit S. Blomjous 1,2, Gayle R. S. Gajadin1, Alexandre E. Voskuyl 2, Louise Falzon2, Jan L. Hoving 4, Irene E. M. Bultink 2 and Marieke M. ter Wee 1,2

Abstract

Objectives. This systematic review assessed which variables are associated with or are predictors for work participation outcomes in patients with systemic lupus erythematosus (SLE).

Methods. A literature search using MEDLINE, The Cochrane Library, Embase and CINAHL was conducted to identify all studies published from inception (1947) to June 2021 on factors related to and/or predicting employment status, absenteeism and/or presenteeism in SLE patients aged ≥18 years. The quality of included articles was assessed using the QUIPS tool. Narrative summaries were used to present the data.

Results. Fifteen studies (nine on associations, four on predictions, and two assessing both) were included, encompassing data of 3800 employed patients. Younger age, Caucasian ethnicity, higher educational level, lower disease activity score, shorter disease duration, absence of specific disease manifestations, higher levels of physical functioning and less physical job demands and higher levels of psychological/cognitive functioning were associated with or predicted favorable work outcomes. Older age, non-Caucasian ethnicity, female gender, never being married, poverty, lower educational level, higher disease activity score, longer disease duration, specific disease manifestations, lower levels of physical functioning, more physical job demands and low job control, less job tenure and lower levels of cognitive functioning were associated with or predicted an unfavorable work outcome. Limitations of the evidence were the quality of the studies and the use of heterogeneous outcome measures, applied statistical methods and instruments used to assess work participation.

Conclusion. We recommend applying the EULAR points to consider for designing, analysing and reporting on work participation in inflammatory arthritis also to SLE studies on work participation, to enhance the quality and comparability between studies and to better understand the impact of SLE on work participation.

Trial registration. registration in PROSPERO (CRD42020161275; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=161275).

Key words: systemic lupus erythematosus, prediction, work participation, absenteeism, presenteeism, employment

Rheumatology key messages

- Unemployment, absenteeism and presenteeism rates of SLE patients are higher than the general population.
- This systematic review summarised explanatory variables and predictors for work outcome in SLE patients.
- By identifying modifiable variables associated with reduced work participation, intervention strategies might be developed.

1Department of Epidemiology and Data Science, Amsterdam Public Health, Amsterdam UMC, 2Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity, Amsterdam UMC Location VUMc, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands, 3Center for Personalized Health, Feinstein Institutes for Medical Research, Northwell Health, New York, USA and 4Department of Public and Occupational Health, Amsterdam Public Health Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands

Submitted 10 June 2021; accepted 11 November 2021
Correspondence to: Marieke M. ter Wee, Amsterdam UMC, Department of Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam Public Health De Boelelaan 1083a, 1007 MB Amsterdam, the Netherlands. E-mail: m.terwee@amsterdamumc.nl
Introduction

Systematic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the involvement of several organ systems, with a peak onset age during the reproductive years, leading to major restrictions in participation in all life areas, including work participation [1, 2]. As patients experience fatigue, reduced physical health, and may undergo intensive treatment, around half of all patients withdraw partly or entirely from the labour force at a young age [3–5]. Not participating in work may lead to lower self-esteem and possible financial problems for patients, and a high societal burden as some patients need a long-term disability pension at a young age [6, 7].

Work participation in SLE has received increasing attention in the past few years, and more recent data has become available on employment status, presenteeism (productivity loss while at work) and absenteeism (workdays lost due to sick leave) in workers with SLE. For example, the unemployment rate in this patient group is estimated between 34% to 62%, depending on the time point of assessment after diagnosis [3, 5, 8, 9]. Absenteeism and work disability are reported to be much higher compared with the general population [2, 3, 8–10]. Presenteeism and absenteeism are challenging to both patients and employers as patients feel more stressed if they are not able to perform their work at their best capacity. And for employers, it means cost increases and co-workers have to work extra to catch up with work for the employee that was absent.

Modifiable variables associated with reduced work participation should be identified to enable the development of intervention strategies to improve work participation in SLE patients in the future. This systematic review aimed to identify and summarize the results of all published longitudinal studies reporting on possible explanatory variables and predictors for work outcome in patients with SLE.

Methods

General methodology

A systematic review of the associations and predictors of work participation in patients with SLE was performed. The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed where possible. The review protocol has been registered in PROSPERO (CRD42020161275). The data underlying this article will be shared on reasonable request to the corresponding author.

Terminology

The term work participation was used to encompass all definitions of work participation in paid work: from employment status to absenteeism (absence from work) and presenteeism (working while sick). For this review, included articles yielded the following definitions of employment status: being employed (having work), being unemployed/health-related job cessation (not having work due to health problems), work loss (employed patients losing their work), work entry (unemployed patients starting work), work disability (having an impairment preventing having work) and unpaid work (performing work without reward). The used definitions of absenteeism were: sick leave (not working because of illness) and short-term disability (not working for a short time due to sickness), and for presenteeism: productivity loss (working but with less productive capacity) and work productivity impairment (having an impairment at work due to health problems resulting in less productivity at work).

Search strategy and eligibility

The search strategy was designed and performed by an experienced librarian (L.F.) and performed using MEDLINE, The Cochrane Library, Embase, CINAHL and PsycINFO from inception (1947) to July 2021. All relevant MeSH and free-text terms were used to represent the concepts of SLE and work participation. They included but were not limited to: ((Lupus Erythematosus, Systemic [MeSH] OR lupus erythematosus.tw OR SLE.tw) AND (Employment [MeSH] OR Absenteeism [MeSH] OR Presenteeism [MeSH] OR absent$.tw or absence.tw OR presenteeism.tw OR productivity.tw OR sick leave.tw)). Details on the search strategy are available in Supplementary Data S1, available at Rheumatology online.

Studies eligible for inclusion in this systematic review needed to report longitudinal relations of explanatory variables [11, 12] on work participation outcome, e.g. absenteeism, presenteeism; and/or employment status. Explanatory variables encompass association results (an aetiological relationship between a risk factor and an outcome variable) and prediction results (a set of variables altogether predicting an outcome variable) [11, 12]. Articles should have reported data on patients with SLE aged ≥18 years. No language restrictions were applied.

Article selection and data extraction

According to the above-mentioned inclusion criteria, title and abstract screening were performed independently by two reviewers (B.S.B. and G.R.S.G.). Thereafter, the remaining potentially relevant articles were screened as full-text. Disagreement between both reviewers on the relevance of an article was discussed with a third reviewer (M.M.tW.) until consensus was reached. Reference lists of the included articles were examined for additional relevant studies.

Data were extracted independently and simultaneously by two reviewers (B.S.B. and G.R.S.G.). Data was collected through a self-designed standardized form: (i) study information (e.g. study design, length of follow-up); (ii) data analyses (e.g. type of statistical analysis and confounders; (iii) baseline data (e.g. gender,
ethnicity, number of employed patients), disease characteristics (e.g. disease duration); and (iv) associations and/or predictors for work participation. Discrepancies in the data extraction between the two reviewers were discussed with the third reviewer (M.M.tW.) until consensus was reached.

Quality assessment of individual studies
The Quality in Prognosis Studies (QUIPS) tool was used to describe the quality of the individual studies [13]. The QUIPS tool includes an assessment of six domains (study participation, study attrition, prognostic factor measurement, outcome measurement, study confounding and statistical analysis and reporting) to assess the risk of bias. The quality of the studies was evaluated independently by two reviewers (B.S.B. and M.M.tW.). Discrepancies regarding the judgement of the quality of the studies were discussed until consensus was reached.

Statistical analysis
A formal meta-analysis could not be performed as considerable heterogeneity was found between all included studies regarding applied outcome measures, applied statistical methods and instruments used to assess work participation. Narrative summaries are therefore used to present the data.

Results
Study selection
In total, 3106 records were identified through database screening and seven records through other sources (Fig. 1). After removing duplicates, 2420 articles remained for title and abstract screening. A total of 2332 records were excluded as these did not comply with the inclusion criteria, of which 829 records did not have work as an outcome measure, and 804 records were abstracts only. From the 88 articles that were read in full text, 73 records were excluded, of which 51 articles did not report on explanatory variables. Reference screening identified 20 additional articles that were excluded after full-text assessment as work was not an outcome measure (n = 3), no full-text availability (n = 1), no (adult) SLE patients included (n = 1), or not reporting on explanatory variables (n = 15). Eventually, 15 relevant studies were included in this review, reporting on longitudinal outcome measures and possible explanatory variables for work participation in patients with SLE [2, 4, 5, 10, 14–24]. Of these 15 studies, nine reported on associations [5, 10, 14–19, 24], four on predictors [4, 20, 21, 23], and two reported on both models [2, 22].

Outcome measures
Table 1 illustrates the outcome measures used in the association and prediction studies. The most frequently used outcome measure was employment status: either being employed [2, 10, 14, 15, 17, 19, 22] or being unemployed [2, 5, 16–18, 22]. Absenteeism was used as an outcome measure in four studies [2, 10, 19, 24]. And presenteeism was reported as either productivity loss [18, 23] or having an impairment of productivity at work due to health problems [5, 10]. Definitions of work outcome measures used in the studies varied widely. For example, being employed was defined at different cut-off points for hours at work weekly [2] or duration of the same or temporary job [15, 17, 22], or being part of the workforce [19]. Other outcome measures on employment status were work disability [4, 19–21], unpaid work [10] and health-related job cessation [2].

Studies reporting on variables associated with work participation
Detailed information on the included eleven studies regarding study design, study population, statistical methods and reported results for all outcome measures are shown in Supplementary Table S1, available at Rheumatology online. These articles reported results of studies in eight different patient cohorts and one registry. Nine studies were performed in the USA [2, 5, 10, 14–18, 24], one in Brazil [22] and one in Hong Kong [19]. No studies were performed in Europe or Africa. SLE was diagnosed using the ACR criteria [25, 26] in nine studies [2, 5, 14–19, 22]. Two studies used alternative classification of disease criteria: one was based on self-reporting [10], and in the other study, SLE was defined either by the International Classification of Disease (ICD) [24], or confirmed by a rheumatologist in combination with having at least two outpatient clinic visits of at least 30 days apart at the rheumatologist [24]. The majority of included patients were of Caucasian ethnicity except in one study, which included only patients of Chinese ethnicity [19]. Most studies included only patients of working age [5, 15–18, 22, 24]. Mean disease duration varied between 5 and 15 years. The duration of follow-up ranged between 6 months and >13 years.

Demographic variables
Associations between demographic variables and work participation were assessed in most studies, as presented in Table 2 [2, 5, 15–19]. Younger age was associated with lower odds for unfavourable employment status as an outcome, e.g. being unemployed, work loss, health-related job cessation or work disability [2, 16–19], but also showed some conflicting results. For example, one study using data from the Lupus Outcome Study (LOS) reported that younger age was significantly associated with being employed (age per year: OR 0.97, 95% CI [0.96, 0.98]) [15]. However, a second study using data from that same database (LOS) reported a non-significant association between higher age and health-related job cessation (OR 0.98, 95% CI [0.95, 1.0]) [2]. Another demographic variable frequently associated with work outcome in studies performed in the USA was ethnicity: work loss in patients of African-American ethnicity occurred more often compared with
Caucasian patients: \( p < 0.001 \) [5], and having a Caucasian ethnicity was associated with being employed: OR 0.72 (95% CI [0.56, 0.92]) [15].

Being higher educated was significantly associated with favorable employment status [2, 15, 18]. For example, having a college grade vs. having no college grade was protective for health-related job cessation (OR 0.27, 95% CI [0.09, 0.84]) [2], and the completion of a bachelor’s degree compared with no bachelor’s degree was associated with being employed (OR 1.8, 95% CI [1.5, 2.2]) [15].

Disease variables

Associations between disease variables and work participation were assessed in nine out of eleven studies [2, 5, 10, 15–19, 24]. The impact of disease duration on work participation was investigated in four studies [16–19]. One study demonstrated longer disease duration to be associated with reduced work entry (only in the disease severity model, not in the final association model: OR 0.94, 95% CI [0.91, 0.97]) [17]. Another study performed in the same cohort reported that longer disease duration was associated with less work loss.
among employed patients (full model: OR 0.93, 95% CI [0.91, 0.94]) [18]. The two remaining studies did not report an association between disease duration and work outcome [16, 19]. The study of Yelin et al. reported that higher disease activity, assessed using patient global assessment, was not associated with work loss among the employed (OR 1.06, 95% CI [0.96, 1.15]) [17]. In contrast, three other studies reported higher disease activity to be associated with an unfavourable work outcome (OR 1.1, 95% CI [1.02, 1.09], [16], OR 1.2, 95% CI [1.0, 1.4], [19], and \( p < 0.0001 \) [5]). The study of Lawson et al. reported a slightly decreased risk of being employed per unit increase in Systemic Lupus Activity Questionnaire (SLAQ) score: OR 0.98 (95% CI [0.97, 0.99]) or being continuously employed (per unit increase in SLAQ score: OR 0.96, 95% CI [0.93, 0.98]) [15]. Depression [17], and some specific disease manifestations of SLE (joint disease/arthritis [2, 5], lung disease [2, 5], cognitive problems [5], and fatigue [5, 19]) were found to be associated with reduced work participation.

**Work variables**

Associations between work variables and work participation were assessed in six out of eleven studies [14–18, 22]. One study reported that job tenure per five years was significantly associated with a reduced risk of work loss (OR 0.8, 95% CI [0.7, 0.9]) [16], and shorter time since last regular work was associated with work entry (OR 0.73, 95% CI [0.62, 0.85]) [17]. High job demands combined with low job control was associated with increased work loss (OR 1.4, 95% CI [1.1, 1.7]) [18]. Higher level of physical functioning was associated with being employed (OR 1.03, 95% CI [1.03, 1.04]), continuous employment (OR 1.05, 95% CI [1.03, 1.07]) [15] and work entry (OR 1.02, 95% CI [1.01, 1.03]) [17]. A lower level of physical functioning showed a small significant association with more work loss (OR 0.99, 95% CI [0.98, 1.00], \( p < 0.05 \)) [17].

**Studies reporting on predictors for work participation**

Detailed information on the six included studies reporting predictors of work are shown in Supplementary Table S2, available at *Rheumatology* online [2, 4, 20–23]. Outcome measures used in the six studies were work disability/health-related job cessation [2, 4, 20, 21], unemployment [22] and productivity loss [23]. Three studies were performed in the USA [2, 20, 21], two in Canada [4, 23] and one in Brazil [22]. The majority of included patients were of Caucasian ethnicity, except for one, in which predominantly patients of Hispanic or African-American ethnicity were included [20]. The mean age of included patients in most studies was of working age [2, 4, 20, 22, 23]. Follow-up duration varied between 12 months and 10 years.

**Demographic variables**

Demographic variables as predictors for work participation were assessed in four out of six studies [4, 20–22], of which education was most often assessed \((n = 3)\) studies [4, 21, 22]. As shown in Table 3, a higher educational level was the most frequently reported predictor

---

**Table 1** Overview of used outcome measures in association and prediction studies

| Presenteeism | Absenteeism | Employment status |
|--------------|-------------|-------------------|
| **Definition** | **Number of studies** | **Definition** | **Number of studies** | **Definition** | **Number of studies** |
| Productivity loss | 2 [18, 23] | Sick leave days | 2 [2, 19] | Being employed | 3 [14, 15, 22] |
| Mean h worked without impairment | 1 [10] | Sick leave h | 2 [10, 24] | Working h per day/week | 2 [10, 19] |
| Work productivity impairment | 1 [5] | Short-term disability h | 1 [24] | Working 24 h per week or less | 1 [2] |
| Unable to work more than two months since diagnosis | 1 [2] | Working <9 months per year | 1 [2] | Working 10+ h at baseline | 1 [2] |
| | | Newly employed | 1 [2] | | |
| | | Length of time until work entry | 1 [17] | | |
| | | Length of time until work loss | 3 [16–18] | | |
| | | Stop working | 1 [2, 5] | | |
| | | Unemployment after three years | 1 [22] | | |
| | | Work disability | 4 [4, 19–21] | | |
| | | Health-related job cessation | 1 [2] | | |
| | | Unpaid work | 1 [10] | | |

h: Hours.
Table 2: Results of association studies reporting on demographic, disease and work-related variables associated with work participation in SLE

| Independent variable          | Presenteeism* Result | OR [95% CI] | Favorable work outcome** Result | OR [95% CI] | Unfavorable work outcome*** Result | OR [95% CI] |
|------------------------------|----------------------|-------------|---------------------------------|-------------|-----------------------------------|-------------|
| Demographic variables        |                      |             |                                 |             |                                   |             |
| Younger age                  | Lower risk (n = 1) [15] |             | Age (continuous): 0.97 [95% CI 0.96, 0.98] [15] |             | Younger age Lower risk (n = 6) [2, 16–19] |             |
| Caucasian ethnicity          | Lower risk (n = 1) [15] |             | Non-Caucasian ethnicity vs Caucasian ethnicity: 0.72 [95% CI 0.56, 0.92] [15] |             | Caucasian ethnicity Lower risk (n = 1) [5] |             |
| Higher educational level     | Lower risk (n = 1) [15] |             | Completion of bachelor’s degree vs no bachelor’s degree: 1.8 [95% CI 1.5, 2.2] [15] |             | Higher educational level Lower risk (n = 1) [18] |             |
| Male gender                  | Lower risk (n = 1) [18] |             | Female vs male: 1.9 [95% CI 1.2, 3.0] [18] |             | Never married Higher risk (n = 1) [17] |             |
| Never married                | Stable (n = 1) [2] |             | Never married vs married: 1.79 [95% CI 1.02, 3.14] [17] |             | North Carolina vs South Carolina: 1.0 [95% CI 0.41, 2.4] [2] |             |

(continued)
| Independent variable | Result | OR [95% CI] | Independent variable | Result | OR [95% CI] | Independent variable | Result | OR [95% CI] |
|----------------------|--------|-------------|----------------------|--------|-------------|----------------------|--------|-------------|
| **Disease variables**# |        |             | **Favorable work outcome** |        |             | **Unfavorable work outcome*** |        |             |
| Moderate disease activity score | Higher risk | (n = 1) [5] | Lower disease activity score | Lower risk | (n = 2) | SLAQ (continuous); 8 0.98 [95%CI 0.97, 0.99] [15] Patient global assessment (continuous); 8 0.89 [95%CI 0.82, 0.98] [17] | Higher disease activity score in the preceding two years | Higher risk | (n = 1) [19] | Mean SELENA-SLEDAI score in preceding 2 years (continuous); 8 1.20 [95%CI 1.02, 1.42] [19] |
| Moderate fatigue score | Higher risk | (n = 1) [5] | Diagnosed with cSLE vs aSLE | Higher risk | (n = 1) [15] | cSLE vs aSLE: 0.62 [95%CI 0.42, 0.91] [15] | Longer disease duration | Lower risk | (n = 1) [18] | Disease duration (continuous); 8 0.93 [95%CI 0.91, 0.94] [18] |
| Severe fatigue score | Higher risk | (n = 1) [5] | Diagnosed with SLE compared with controls | Higher risk | (n = 1) [10] | SLE vs controls: P < 0.001 [10] | Depression | Higher risk | (n = 1) [17] | CES-D (continuous); 8 1.03 [95%CI 1.01, 1.05] [17] |
| Skin disease activity | Higher risk | (n = 1) [5] | Dialysis | Higher risk | (n = 1) [15] | Dialysis vs no dialysis: 0.74 [95%CI 0.56, 0.96] [15] | Thrombotic manifestations | Higher risk | (n = 1) [16] | Thrombotic manifestations (y/n): 8.2 [95%CI 1.7, 5.9] [16] |
| Mild lung disease activity | Higher risk | (n = 1) [5] | Fewer lung manifestations in past 5 years | Lower risk | (n = 1) [17] | Lung manifestations in past 5 years (categorical): 0.45 [95%CI 0.20, 1.00] [17] | Severe musculoskeletal manifestations | Higher risk | (n = 1) [16] | Severe musculoskeletal manifestations (y/n): 1.7 [95%CI 1.2, 2.5] [16] |
| Moderate lung disease activity | Higher risk | (n = 1) [5] | Moderate vs no lung disease activity; ρ < 0.0001 [5] | Arthritis | Higher risk | (n = 1) [2] | Arthritis (y/n): 3.3 [95%CI 1.2, 8.8] [2] |        |             |
| Severe lung disease activity | Higher risk | (n = 1) [5] | Severe vs no lung disease activity; ρ < 0.0001 [5] | Pleuritis | Higher risk | (n = 1) [2] | Pleuritis (y/n): 2.3 [1.1, 4.6] [2] |        |             |
| Mild stroke syndrome | Higher risk | (n = 1) [5] | Mild vs no stroke syndrome; ρ = 0.011 [5] | Higher fatigue | Higher risk | (n = 1) [19] | FACIT-F (continuous); 8 1.06 [95%CI 1.01, 1.10] [19] |        |             |
| Moderate stroke syndrome | Higher risk | (n = 1) [5] | Moderate vs no stroke syndrome; ρ = 0.005 [5] |        |             |        |             |
| Severe stroke syndrome | Higher risk | (n = 1) [5] | Severe vs no stroke syndrome; ρ = 0.0005 [5] |        |             |        |             |  |  |

(continued)
| Independent variable | Result | OR [95% CI] | Independent variable | Result | OR [95% CI] | Independent variable | Result | OR [95% CI] |
|----------------------|--------|-------------|----------------------|--------|-------------|----------------------|--------|-------------|
| **Presenteeism***     |        |             |                      |        |             |                      |        |             |
| Moderate cognitive disease activity | Higher risk $(n = 1)$ [5] | Moderate vs no cognitive disease activity: $p = 0.0034$ [5] | | | | | | |
| Severe cognitive disease activity | Higher risk $(n = 1)$ [5] | Severe vs no cognitive disease activity: $p < 0.0001$ [5] | | | | | | |
| Mild muscle disease activity | Higher risk $(n = 1)$ [5] | Mild vs no muscle disease activity: $p = 0.054$ [5] | | | | | | |
| Moderate muscle disease activity | Higher risk $(n = 1)$ [5] | Moderate vs no muscle disease activity: $p < 0.0001$ [5] | | | | | | |
| Mild joint disease activity | Higher risk $(n = 1)$ [5] | Mild vs no joint disease activity: $p = 0.037$ [5] | | | | | | |
| Moderate joint disease activity | Higher risk $(n = 1)$ [5] | Moderate vs no joint disease activity: $p < 0.0001$ [5] | | | | | | |
| Severe joint disease activity | Higher risk $(n = 1)$ [5] | Severe vs no joint disease activity: $p < 0.0001$ [5] | | | | | | |
| Having SLE compared with controls | Higher risk $(n = 1)$ [10, 24] | SLE vs controls: $p < 0.001$ [10] SLE vs controls: $p < 0.01$ [24] | | | | | | |
| **Favorable work outcome*** |        |             |                      |        |             |                      |        |             |
| Work variables | Higher level of physical functioning Lower $(n = 2)$ [15–17, 19] | SF-36 physical functioning (continuous): 1.05 [1.03, 1.07] [15] SF-36 physical functioning scale (continuous): 8.102 [95%CI 1.01, 1.03] [17] | | | | | | |
| | | | | | | | | | |
| **Unfavorable work outcome*** |        |             |                      |        |             |                      |        |             |
| Work variables | Higher level of physical functioning Lower $(n = 1)$ [17] | SF-36 physical functioning scale (continuous): 8.099 [95%CI 0.98, 1.00] [17] | | | | | | |

(continued)
**Table 2 Continued**

| Presenteeism* | Favorable work outcome** | Unfavorable work outcome*** |
|---------------|--------------------------|-----------------------------|
| Independent variable | Result | OR [95% CI] | Independent variable | Result | OR [95% CI] | Independent variable | Result | OR [95% CI] |
| Shorter time since last regular work | Lower risk \( n = 1 \) [17] | | Years since regular work (continuous): 8 0.73 [95%CI 0.62, 0.85] [17] | Higher risk \( n = 1 \) [18] | | Sum of physical job demands (continuous): 8 1.06 [95%CI 1.0, 1.1] [18] |
| Being employed after three years compared with baseline | Lower risk \( n = 1 \) [22] | | Being employed at follow-up compared with being employed at study entry: 2.25 [95%CI 1.4, 3.7] [22] | Higher cognitive functioning | Lower risk \( n = 1 \) [17] | MOS cognitive functioning scale (continuous): 8 0.98 [95%CI 0.97, 0.99] |
| Currently employed at follow-up based on obesity status | Lower risk \( n = 1 \) [14] | | Currently employed at follow-up based on obesity status at baseline for non-obese vs obese patients: 0.5 [95%CI 0.3, 0.8] [14] | Job tenure per 5 years | Lower risk \( n = 1 \) [16] | Job tenure per 5 years (continuous): 8 0.9 [95%CI 0.7, 0.97] [16] |
| | | | | High job demands and low control | Higher risk \( n = 1 \) [18] | High job demands low control (y/n): 1.4 [95%CI 1.1, 1.7] [18] |

The number of studies is indicated. All mentioned associations are statistically significant. In the case of multiple models per study, the outcome of the first model or most extensive model is shown. In the Online Supplementary Table 1, available at Rheumatology online, the other outcomes can be found. The studies of Drenkard, Garris and Narayanan et al. did not show ORs; therefore \( p \)-values are shown. *Presenteeism work outcomes: work productivity impairment, work hours missed due to SLE, work hours missed for another reason. **Favorable work outcomes: being employed, being continuously employed, length of time until work loss at first specific SLE manifestation, work worked, work entry among unemployed. ***Unfavorable work outcomes: loss of days from the workforce and non-workforce activity, length of time until work loss, health-related job cessation, work loss, work disability over ten years after diagnosis, work loss among employed at diagnosis, work loss among employed. #Disease activity measured by Systemic Lupus Activity Questionnaire (SLAQ), patient global assessment and Safety of Estrogens in SLE National Assessment SLE Disease Activity Index (SELENA-SLEDAI), aSLE: adulthood-onset SLE; CES-D: Center for Epidemiologic Studies Depression Scale; cSLE: childhood-onset SLE; FACIT-F: Functional Assessment of Chronic Illness Therapy Fatigue; MOS: Medical Outcomes Study; OR: odds ratio; SF36: Short Form 36; SLAQ: Systemic Lupus Activity Questionnaire.
**TABLE 3** Result of prediction studies reporting on demographic, disease and work-related variables predicting work participation in SLE

| Work outcomes* | Unfavorable work outcome |
|----------------|-------------------------|
| Predictor      | Result | Coefficient (s.e.) | Predictor | Result | OR [95% CI] |
| Demographic variables | | | | |
| Younger age    | Lower risk | | Age (continuous): β 1.1 | | [95% CI 1.02, 1.12] |
| (n = 1) [20] | | | [20] | | |
| Male gender    | Higher risk | | Male vs female: 4.5 | | [95% CI 1.3, 15.9] |
| (n = 1) [20] | | | [20] | | |
| Poverty        | Higher risk | | Poverty vs no poverty: 2.9 | | [95% CI 1.2, 7.0] |
| (n = 1) [20] | | | [20] | | |
| Higher educational level | Lower risk | | Finished high school vs more than high school: 0.39 | | [95% CI 0.21, 0.7] [4] |
| (n = 3) [4, 21, 22] | | | High school education or less vs beyond high school: 3.9 | | [95% CI 1.9, 8.2] [21] |
| Disease variables | | | Education (continuous): β 0.09 | | [95% CI 0.01, 0.4] [22] |
| Higher pain score | Higher risk | | First SLEDAI-2K score (continuous): 8.1 | | [95% CI 1.00, 1.08] [4] |
| n = 1 [23] | | | 1.4 | | |
| Pain score (continuous): β 0.16 | | | SLAM-R average (continuous): β 1.3 | | [95% CI 1.1, 1.4] [20] |
| (0.06) [23] | | | [20] | | |
| Higher disease activity at diagnosis | Stable risk | | Total disease duration (continuous): 8.1 | | [95% CI 1.1, 1.4] [20] |
| (n = 1) [4] | | | 2 | | |
| Higher disease activity during the study | Higher risk | | Total disease duration (continuous): β 1.2 | | [95% CI 1.1, 1.4] [20] |
| (n = 1) [20] | | | [20] | | |
| Longer total disease duration | Higher risk | | | | |
| (n = 1) [20] | | | | | |
| Damage accrual | Higher risk | | SDI at last visit (continuous): β 1.4 | | [95% CI 1.1, 1.7] [20] |
| (n = 1) [20] | | | [20] | | |
| Hypertension | Higher risk | | Hypertension vs no hypertension: 2.2 | | [95% CI 1.2, 4.3] [4] |
| (n = 1) [4] | | | [4] | | |
| Fibromyalgia | Higher risk | | Fibromyalgia vs no fibromyalgia: 5.1 | | [95% CI 2.6, 10.0] [4] |
| (n = 1) [4] | | | [4] | | |
| Depression | Higher risk | | BDI >10 (depression) vs BDI <10: 2.3 | | [95% CI 1.0, 5.2] [22] |
| (n = 1) [22] | | | [22] | | |
| Pleuritis | Higher risk | | Significant, data were not presented | | [2] |
| (n = 1) [2] | | | [2] | | |
| Moderate or high aCL titers | Higher risk | | Moderate or high aCL titers vs low aCL titers: 2.1 | | [95% CI 1.2, 4.9] [22] |
| (n = 1) [22] | | | [22] | | |
| Impairment in complex attention | Higher risk | | Impairment in complex attention vs no impairment: 2.2 | | [95% CI 1.1, 3.8] [22] |
| (n = 1) [22] | | | [22] | | |
| Impairment in memory | Higher risk | | Impairment in memory vs no impairment: 3.6 | | [95% CI 2.1, 6.4] [22] |
| (n = 1) [22] | | | [22] | | |
| Impairment in executive functions | Higher risk | | Impairment in executive functions vs no impairment: 1.8 | | [95% CI 1.2, 7.3] [22] |
| (n = 1) [22] | | | [22] | | |
| (continued) | | | | | |
for a favorable employment status as an outcome measure in three studies, including permanent work disability/health-related job cessation and unemployment in patients being employed previously [4, 21, 22]. Having graduated from high school was found to be protective for being ever work disabled (OR 0.39, 95% CI [0.21, 0.7]) [4], and high school education or less was strongly predictive for work disability (OR 3.9, 95% CI [1.9, 8.2], overall model \( p < 0.0001 \)) [21]. Finally, fewer years of education predicted unemployment after three years (OR 0.13, 95% CI [0.01, 0.5]) [22].

**Disease variables**

Disease variables as predictors for work participation were assessed in all six studies [2, 4, 20–23], of which disease activity was most often used (n = 3 studies) [4, 20, 21]. Higher disease activity score at diagnosis showed an unclear effect on employment status as no studies showed a significant relationship between disease activity at diagnosis and work participation. The study of Al Dhanhani et al. reported that high disease activity score at diagnosis, assessed using SLE Disease Activity Index 2000 (SLEDAI-2k), was not a predictor for work disability (OR 1.0, 95% CI [1.0, 1.1]) [4]. In contrast, the study of Partridge et al. reported a non-significant slightly increased risk (OR 1.1, 95% CI [0.9, 1.2]) for work disability in patients with higher disease activity score at diagnosis, assessed using the Systemic Lupus Activity Measure (SLAM) score [21].

**Work variables**

Only two studies assessed work variables as possible predictors [21, 23]. A higher level of physical and psychological functioning predicted less presenteeism (coefficient 0.18, S.E. 0.08, \( p = 0.0198 \)) [23], and higher physical job demands strongly predicted more work disability (OR 2.8, 95% CI [1.4, 5.4]) [21].

**Assessments of risk of bias**

In nearly all studies, the quality was assessed as moderate to poor, as assessed with the QUIPS tool (Table 4). A high risk of bias in the domain ‘study attrition’ was judged in all but one study [22], as these studies did not provide information on patients who dropped out of the study. The risk of bias was judged low in nine studies as clear definitions of outcomes were provided and methods and setting of outcome measures were valid and the same for all study participants [10, 14–18, 20, 21, 23]. Furthermore, the risk of bias due to confounding was judged high in most studies as no confounders were assessed [2, 4, 5, 14, 15, 17–19, 22, 24].

**Discussion**

This study is the first to systematically review explanatory variables for work participation in patients with SLE. The results of this review showed that being of younger age, having a Caucasian ethnicity, higher educational level, lower disease activity score, a shorter...
disease duration, absence of specific disease manifestations, higher levels of physical functioning, less physical job demands and higher levels of psychological/cognitive functioning were associated with or predicted favorable work participation levels. Older age, non-Caucasian ethnicity, female gender, never being married, poverty, lower educational level, higher disease activity score, longer disease duration, specific disease manifestations, lower levels of physical functioning, more physical job demands and low job control, less job tenure, and lower levels of cognitive functioning were associated with or predicted an unfavorable work outcome.

Demographic variables were most often assessed in the included studies in this review. For example, having a younger age protected against unfavorable work participation outcomes in association and prediction studies [2, 16–20]. This is in line with three published reviews on variables related to work productivity in patients with other rheumatic diseases [27–29]. Furthermore, patients diagnosed with SLE at a young age might adapt their choice of education and job type to fit the presence of their disease early in life. A recent study reported a high rate of work participation in adulthood among patients with juvenile-onset SLE [30]. Studies on the influence of gender on work participation in SLE revealed conflicting results. Being male was associated with a lower risk of work loss/health-related job cessation [2, 18], but was predictive for higher work disability rates [20]. This finding is remarkable as SLE predominantly affects females resulting in low numbers of males being included in the studies [31]. It is known that males with SLE tend to have a higher organ damage score [32], and, therefore, might experience work disability more frequently. Findings on education levels are in accordance with results of studies in patients diagnosed with other rheumatic diseases [27–29]. A possible explanation might be that higher education jobs are more often white-collar jobs (more sedentary), which may be more flexible and easier to maintain than blue-collar jobs.

Five studies showed that high disease activity scores were associated with or predicted an unfavorable employment status from the included studies that assessed disease variables [5, 15, 17, 19, 20]. Better treatment of disease activity might therefore be a target to enhance work participation. Remarkably, the disease activity score at diagnosis was no predictor of work participation, underlining the importance of effective treatment to lower disease activity [4, 21]. Other disease variables associated with work participation were specific disease manifestations (lung disease [2, 5], cognitive problems [5, 22], depression [17, 22]) and disease duration. This finding seems in line with the literature, as having cognitive problems or depressions are known factors associated with increased work disability [33–35].

As advised by Outcome Measures in Rheumatoid Arthritis (OMERACT), contextual factors play an essential role in work participation, especially work-related factors as job demands [36]. These factors are modifiable, and could help maintain employment. Only eight studies included work variables in their analyses [14–18, 21–23]. These studies demonstrated that lower levels of autonomy (high job demands and low control) [18], physical functioning [15, 17, 23], less physical job demands [18, 21] and higher levels of psychological functioning/higher cognitive functioning [17, 23] were related with poorer work participation both in association and prediction studies, which is also found in studies in other rheumatic diseases [27–29].

**TABLE 4** Results of risk of bias assessment using QUIPS

| Study participation | Study attrition | Prognostic factor measurement | Outcome measurement | Study confounding | Statistical analysis and reporting |
|---------------------|----------------|-----------------------------|---------------------|------------------|----------------------------------|
| Al Dhanhani, 2009   | ±              | –                           | –                   | ±                | –                                |
| Appenzeller, 2009   | ±              | –                           | ±                   | ±                | –                                |
| Bertoli, 2006       | +              | –                           | ±                   | ±                | –                                |
| Campbell, 2009      | ±              | –                           | ±                   | +                | NA                               |
| Clarke, 1993        | ±              | –                           | ±                   | –                | ±                                |
| Drenkard, 2014      | +              | –                           | ±                   | –                | –                                |
| Garris, 2013        | –              | –                           | –                   | +                | –                                |
| Katz, 2011          | –              | –                           | –                   | +                | –                                |
| Lawson, 2014        | –              | –                           | ±                   | –                | ±                                |
| Mok, 2008           | –              | NA                          | ±                   | –                | –                                |
| Narayanan, 2013     | ±              | NA                          | ±                   | –                | –                                |
| Partridge, 1997     | –              | –                           | –                   | +                | ±                                |
| Yelin, 2007         | –              | –                           | ±                   | –                | ±                                |
| Yelin, 2009         | –              | –                           | –                   | –                | –                                |
| Yelin, 2012         | –              | –                           | –                   | –                | –                                |

– = high risk of bias; ± = moderate risk of bias; + = low risk of bias.
Although a decade ago a systematic review on work disability in patients with SLE was published [37], we now were able to include eleven new longitudinal studies on work participation in SLE [2, 4, 5, 10, 14–17, 19, 22, 24]. Our systematic review comprises more studies including work-related factors and demonstrates that several work variables are associated with work participation. This finding supports the idea that future interventions focusing on changing the work environment should be further explored to improve work participation of patients with SLE [38]. Also, the challenge of individual countries having different work and healthcare systems that have an impact on work on itself should be taken into account in future studies.

This study has several limitations. First, the quality of the included studies was judged moderate-to-poor according to the QUIPS tool, limiting the strength of the evidence. Second, most of the included studies originated from the USA, while no studies from Europe and Africa could be included. The results of this review can therefore not be generalized to SLE patients around the world. Third, most odds ratios were small, and CIs were large, resulting in non-significant results. Fourth, the studies included in this review were difficult to compare due to the heterogeneity in the populations investigated, measurement instruments and outcome measures used. Heterogeneous outcome measures, as well as diverse use of included variables are a known problem in research on work participation in patients with other rheumatic diseases [37, 39–41]. To enhance the comparability between studies and increase the value of research, a EULAR task force on work participation published EULAR points to consider for designing, analysing and reporting of studies with work participation as an outcome, specifically for inflammatory arthritis [42]. To standardize demographic, disease and work outcome measures used in studies, it is desirable to define a core outcome set of variables [30]. We therefore recommend applying the EULAR points to consider also in SLE studies to enhance and improve the quality of studies.

At last, we propose a research agenda for future research, focusing on extensive studies investigating both predictors for work loss among employed patients and work entry among unemployed patients. In addition, exploring the influence of more flexible work options since the COVID-19 pandemic on work participation in SLE patients might be an interesting topic for future research. It might be beneficial for SLE patients if they have the option to work from home most days of the week to avoid or reduce commuting time, long days at the office and no flexible hours. This may help researchers to explore modifiable variables in future intervention studies aiming to enhance work participation in patients with SLE.

**Conclusion**

In conclusion, despite the heterogeneity of the included studies, younger age, Caucasian ethnicity, lower educational level, lower disease activity, shorter disease duration, absence of specific disease manifestations, higher levels of physical functioning, less physical job demands and higher levels of psychological/cognitive functioning were associated with or predicted work participation. We recommend applying the EULAR points to consider for designing, analysing and reporting of studies with work participation as an outcome in inflammatory arthritis, as well as in SLE studies, to enhance the quality of studies and comparability between studies; to better understand the impact of SLE and treatment on work participation.

**Funding:** No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.

**Disclosure statement:** The authors have declared no conflicts of interest.

**Data availability statement**

The data underlying this article are available in the article and in its online supplementary material.

**Supplementary data**

Supplementary data are available at *Rheumatology* online.

**References**

1. Elera-Fitzcarrald C, Fuentes A, González LA et al. Factors affecting quality of life in patients with systemic lupus erythematosus: important considerations and potential interventions. Expert Rev Clin Immunol 2018;14:915–31.
2. Campbell R Jr, Cooper GS, Gilkeson GS. The impact of systemic lupus erythematosus on employment. J Rheumatol 2009;36:2470–5.
3. Bultink IEM, Turkstra F, Dijkmans BAC et al. High prevalence of unemployment in patients with systemic lupus erythematosus: association with organ damage and health-related quality of life. J Rheumatol 2008;35:1053–7.
4. Al Dhanhani AM, Gignac MAM, Su J et al. Work disability in systemic lupus erythematosus. Arthritis Rheum 2009;61:378–85.
5. Drenkard C, Bao G, Dennis G et al. Burden of systemic lupus erythematosus on employment and work productivity: data from a large cohort in the southeastern United States. Arthritis Care Res 2014;66:878–87.
6. Gordon C, Isenberg D, Lerstrom K et al. The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey. Rheumatology 2013;52:2292–301.
7. Robinson D, Aguilar D, Schoenwetter M et al. Impact of systemic lupus erythematosus on health, family, and work: the patient perspective. Arthritis Care Res 2010;62:266–73.
8. Ekblom-Kullberg S, Kautinaen H, Alha P et al. Education, employment, absenteeism, and work
disability in women with systemic lupus erythematosus. Scand J Rheumatol 2015;44:157–62.

9 Utset TO, Baskaran A, Segal BM et al. Work disability, lost productivity and associated risk factors in patients diagnosed with systemic lupus erythematosus. Lupus Sci Med 2015;2:e000058.

10 Garris C, Oglesby A, Sulcs E et al. Impact of systemic lupus erythematosus on burden of illness and work productivity in the United States. Lupus 2013;22:1077–86.

11 Tripepi G, Jager KJ, Dekker FW et al. Testing for causality and prognosis: etiological and prognostic models. Kidney Int 2008;74:1512–5.

12 van Diepen M, Ramspek CL, Jager KJ et al. Prediction versus aetiology: common pitfalls and how to avoid them. Nephrol Dial Transplant 2017;32:ii1–ii5.

13 Hayden JA, van der Windt DA, Cartwright JL et al. Assessing bias in studies of prognostic factors. Ann Intern Med 2013;158:280–6.

14 Katz P, Yazdany J, Julian L et al. Impact of obesity on functioning among women with systemic lupus erythematosus. Arthritis Care Res 2011;63:1357–64.

15 Lawson EF, Hersh AO, Trupin L et al. Educational and vocational outcomes of adults with childhood- and adult-onset systemic lupus erythematosus: nine years of follow-up. Arthritis Care Res 2014;66:717–24.

16 Yelin E, Tonner C, Trupin L et al. Longitudinal study of the impact of incident organ manifestations and increased disease activity on work loss among persons with systemic lupus erythematosus. Arthritis Care Res 2012;64:169–75.

17 Yelin E, Tonner C, Trupin L et al. Work loss and work entry among persons with systemic lupus erythematosus: comparisons with a national matched sample. Arthritis Rheum 2009;61:247–58.

18 Yelin E, Trupin L, Katz P et al. Work dynamics among persons with systemic lupus erythematosus. Arthritis Rheum 2007;57:56–63.

19 Mok CC, Cheung MY, Ho LY et al. Risk and predictors of work disability in Chinese patients with systemic lupus erythematosus. Lupus 2008;17:1103–7.

20 Bertoli AM, Fernandez M, Alarcon GS et al. Systemic lupus erythematosus in a multiethnic US cohort LUMINA (XLI): factors predictive of self-reported work disability. Ann Rheum Dis 2006;66:12–7.

21 Partridge AJ, Karlson EW, Daltroy LH et al. Risk factors for early work disability in systemic lupus erythematosus: results from a multicenter study. Arthritis Rheum 1997;40:2199–206.

22 Appenzeller S, Cendes F, Costallat LT. Cognitive impairment and employment status in systemic lupus erythematosus: a prospective longitudinal study. Arthritis Rheum 2009;61:680–7.

23 Clarke AE, Esdaile JM, Bloch DA et al. A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs. Arthritis Rheum 1993;36:1548–59.

24 Narayanan S, Wilson K, Oglesby A et al. Economic burden of systemic lupus erythematosus flares and comorbidities in a commercially insured population in the United States. J Occup Environ Med 2013;55:1262–70.

25 Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.

26 Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.

27 Fraenunder R, Pinheiro M, D M, Ciconelli RM. Variables related to work productivity loss in patients with ankylosing spondylitis. Rev Bras Reumatol 2013;53:303–9.

28 de Croon EM, Sluiter JK, Nijsen TF et al. Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2004;63:1362–7.

29 Decuman S, Smith V, Verhaeghe STL et al. Work participation in patients with systemic sclerosis: a systematic review. Clin Exp Rheumatol 2014;32:S-206–13.

30 Groot N, Kardolus A, Bijl M et al. Effects of childhood-onset SLE on academic achievements and employment in adult life. J Rheumatol 2021;48:915–23.

31 Pons-Estel GJ, Alarcón GS, Scofield L et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010;39:257–68.

32 Lu L-J, Wallace DJ, Ishimori ML et al. Review: ale systemic lupus erythematosus: a review of sex disparities in this disease. Lupus 2010;19:119–29.

33 Lagerfeld SE, Bültmann U, Franche RL et al. Factors associated with work participation and work functioning in depressed workers: a systematic review. J Occup Rehabil 2010;20:275–92.

34 Schiavolin S, Leonardi M, Giovannetti AM et al. Factors related to difficulties with employment in patients with multiple sclerosis: a review of 2002-2011 literature. Int J Rehabil Res 2013;36:105–11.

35 Klaver KM, Duijts SFA, Engelhardt EG et al. Cancer-related cognitive problems at work: experiences of survivors and professionals. J Cancer Surviv 2020;14:168–78.

36 Tang K, Boonen A, Verstappen SMM et al. Worker productivity outcome measures: OMERACT filter evidence and agenda for future research. J Rheumatol 2014;41:165–76.

37 Baker K, Pope J. Employment and work disability in systemic lupus erythematosus: a systematic review. Rheumatology 2009;48:281–4.

38 Hoving JL, van Zwieten MCB, van der Meer M et al. Work participation and arthritis: a systematic overview of challenges, adaptations and opportunities for interventions. Rheumatology 2013;52:1254–64.

39 ter Wee MM, Lemus WF, Usan H et al. The effect of biological agents on work participation in rheumatoid arthritis patients: a systematic review. Ann Rheum Dis 2012;71:161–71.

40 van der Burg LR, Ter Wee MM, Boonen A. Effect of biological therapy on work participation in patients with
41 Marques ML, Alunno A, Boonen A et al. Methodological aspects of design, analysis and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis: results of two systematic literature reviews informing EULAR points to consider. RMD Open 2021;7:e001522.

42 Boonen A, Putrik P, Marques ML et al. EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis. Ann Rheum Dis 2021;80:1116–23.